CuATSM: Australian trial gives new hope for Parkinson’s disease treatment
 

If this is true, let’s get on with it! Wow!

Australian trial gives new hope for Parkinson’s disease treatment

mcc950 parkinson's disease
 

So, apparently, you can buy this drug now. Although this most recent report includes copper with dose? Anyone interested?

World-first pill may stop Parkinson's | The New Daily

MCC95�(CP-456773) | Immunology & Inflammation related inhibitor | Read Reviews & Product Use Citations
Selleck USA Tel: (832) 582-8158 sales@selleckchem.com


MCC95� | The Science of Parkinson's


MCC95� as a New Therapy for Parkinson’s Disease - BioTechniques

ashleyk,

You seem to be saying that CuATSM is MCC950 plus copper.

I've read the CuATSM article. I can't see any connection between CuATSM and MCC950.

Jeff

CuATSM Phase 1 abstract
 

There is also an abstract available, from the WORLD CONGRESS ON PARKINSON҅S DISEASE AND RELATED DISORDERS (2019):

(4MB PDF - see page 119)

https://www.iaprd-world-congress.com...VxE2UiPzLv-YgE

To Jefferyn
 

In my post I firstly sited the article below. The drug itself seems to be the same in both reports, the only difference is copper.



https://thenewdaily.com.au/life/well...nsons-therapy/

I can see no relationship at all between CuATSM and MCC950. CuATSM is targetting the electron transport chain within mitochondria. MCC950 is targetting the inflammatory activity of microglia.

In the article about CuATSM, the section at the end, titled "Australia continues to forge ahead" (and the photograph of MJF), refer to the work on MCC950 being done at the University of Queensland. I can see how this section could cause confusion.

cuatsm
 

Jeffrey, you're right. I misread the article. It seems cuatsm was first tried for people with ALS and the drugs purpose is to deliver more copper to the brain?



ALS Progression May Be Slowed With CuATSM Treatment, Trial Shows

Thanks for the link, ashleyk.

As it says in your linked article, "CuATSM is a small artificial molecule [that contains a copper atom,] that is able to deliver copper to cells containing damaged mitochondria ...".

As it says in the Conclusions section of the PD Phase 1 abstract (see link above): "Based on treatment tolerance and improvement in UPDRS and PDQ-39 over 24 weeks at [recommended dose], further development in a randomized, placebo-controlled trial is justified."